You are here: Industry Insights > IPO

News List

Gritstone Oncology files for $80M IPO fiercebiotech
August 24, 2018
Gritstone Oncology, the immuno-oncology upstart that has pocketed more than $194 million in venture capital, is going public. The Bay Area biotech is looking to raise up to $80 million in its IPO........
Principia Biopharma lines up for $86M IPO fiercebiotech
August 22, 2018
Principia Biopharma has filed to raise up to $86.3 million in its IPO to carry its lead asset into phase 3. The company's BTK inhibitor is currently in phase 2 trials for the autoimmune skin disease pemphigus and is also being developed for immune thrombo
Principia Biopharma lines up for $86M IPO fiercebiotech
August 21, 2018
Principia Biopharma has filed to raise up to $86.3 million in its IPO to carry its lead asset into phase 3. The company's BTK inhibitor is currently in phase 2 trials for the autoimmune skin disease pemphigus and is also being developed for immune thrombo
Liquidia files for IPO to challenge United Therapeutics in PAH fiercebiotech
July 09, 2018
Liquidia Technologies has filed for a $57.5 million IPO to take its twist on United Therapeutics’ Tyvaso through phase 3.
IPO bonanza continues with $150M listing for CAR-T player Autolus fiercebiotech
June 25, 2018
Biotech IPOs continue to come thick and fast this week, with U.K. T-cell therapy specialist Autolus the latest to list with an impressive $150 million raise.
Aptinyx, Magenta lead biotech IPO flurry ahead of summer lull fiercebiotech
June 25, 2018
No fewer than five biotech IPOs debuted Thursday, raising more than $460 million and with more in the offing if underwriters take up further options.
Eidos Therapeutics raises $106M IPO to advance ATTR med fiercebiotech
June 25, 2018
Rare disease biotech Eidos Therapeutics priced its IPO at $17 a share, hauling in about $106.3 million to push its treatment for transthyretin (TTR) amyloidosis through the clinic.
Tricida files for $150M IPO to fund kidney disease drug approval fiercebiotech
June 11, 2018
Tricida has filed to raise $150 million to bring a chronic kidney disease drug to market. Proceeds from the planned IPO will set Tricida up to file for FDA approval of TRC101 and start building up the 80- to 100-person sales team it wants to commercialize
JHL Biotech raises $106M in pre-IPO funding biospectrumasia
May 31, 2018
JHL will allocate its new capital to support clinical trials and further development of its biosimilar portfolio.
Verrica seeks $86M IPO to take on compounded dermatology drug fiercebiotech
May 29, 2018
Verrica Pharmaceuticals has filed to raise $86 million from public investors. The planned IPO will give Verrica the money it needs to take a treatment for viral skin infection molluscum through phase 3 and onto the market.

Previous page 1 2 3 4 5 6 7 8 9 Next page